Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E Choy

SAT0480 Comparative Effectiveness of Secukinumab and Infliximab in Psoriatic Arthritis Assessed by Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data

2017

English

SP0125 Inflammation and Cardiovascular Disease – Relevant Metabolic Biomarkers

2017

English

Related publications

Matching-Adjusted Indirect Comparison: Secukinumab Versus Infliximab in Biologic-Naive Patients With Psoriatic Arthritis

Journal of Comparative Effectiveness Research

Health Policy

2019

English

Comparative Effectiveness of Treatments for Relapsed or Refractory Mantle Cell Lymphoma (R/R McL), Using Matching Adjusted Indirect Comparison

English

Real-World Data on Secukinumab Use for Psoriatic Arthritis and Ankylosing Spondylitis

Therapeutic Advances in Musculoskeletal Disease

English

Prm236 - Calibrating Matching Adjusted Indirect Comparison Estimate to Real-World Population

English

Matching-Adjusted Indirect Comparison of Benralizumab Versus Interleukin-5 Inhibitors: Systematic Review

European Respiratory Journal

English

Interleukin-17inhibition With Secukinumab Improves Sudomotor Dysfunction in Psoriatic Arthritis

International Journal of Pharmacy and Pharmaceutical Sciences

Pharmacology

Pharmaceutical Science

2018

English

Comparative Efficacy of Combination Immunotherapy and Targeted Therapy in the Treatment of BRAF-mutant Advanced Melanoma: A Matching-Adjusted Indirect Comparison

English

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results From the Phase 3 FUTURE 1 Study

ACR Open Rheumatology

2019

English

Pms28 - Secukinumab Versus Infliximab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E Choy

SAT0480 Comparative Effectiveness of Secukinumab and Infliximab in Psoriatic Arthritis Assessed by Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data

SP0125 Inflammation and Cardiovascular Disease – Relevant Metabolic Biomarkers

Related publications

Matching-Adjusted Indirect Comparison: Secukinumab Versus Infliximab in Biologic-Naive Patients With Psoriatic Arthritis

Comparative Effectiveness of Treatments for Relapsed or Refractory Mantle Cell Lymphoma (R/R McL), Using Matching Adjusted Indirect Comparison

Real-World Data on Secukinumab Use for Psoriatic Arthritis and Ankylosing Spondylitis

Prm236 - Calibrating Matching Adjusted Indirect Comparison Estimate to Real-World Population

Matching-Adjusted Indirect Comparison of Benralizumab Versus Interleukin-5 Inhibitors: Systematic Review

Interleukin-17inhibition With Secukinumab Improves Sudomotor Dysfunction in Psoriatic Arthritis

Comparative Efficacy of Combination Immunotherapy and Targeted Therapy in the Treatment of BRAF-mutant Advanced Melanoma: A Matching-Adjusted Indirect Comparison

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results From the Phase 3 FUTURE 1 Study

Pms28 - Secukinumab Versus Infliximab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.